In HER2-Positive Breast Cancers, PARP Inhibitors May Have Clinical Utility

[News]

Poly (ADP-Ribose) polymerase (PARP) inhibitors, shown to have clinical activity when used alone in women with familial breast and ovarian cancers linked to BRCA mutations, may be a novel treatment strategy in women with HER2-positive breast cancers, according to the results of a study published in Cancer Research, a journal of the American Association for Cancer Research...

More... (http://www.medicalnewstoday.com/releases/250366.php)